GlassScriptPhysician profile
Brenda L Ford
NPI 1811323520
$4,283.06
in general payments reported to CMS, 2019-2025
17 companies · $74.99 in 2025
The $74.99 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $748 · 2022: $1,637 · 2023: $1,211 · 2024: $612 · 2025: $74.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,898.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,898.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,908.38 | 2021-2025 | Superion Indirect Decompression System, Wavewriter Alpha Prime 16, General - Pain Management |
| Nalu Medical, INC. | $919.17 | 2022 | |
| Nevro Corp. | $294.34 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $272.27 | 2021-2024 | Xtampza, Belbuca |
| Scilex Pharmaceuticals INC. | $228.13 | 2021-2023 | Ztlido |
| Vertos Medical, INC. | $148.83 | 2023-2024 | Mild Device Kit |
| Redhill Biopharma INC. | $135.71 | 2021 | |
| Medtronic, INC. | $104.65 | 2022-2023 | Synchromedii |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.70 | 2022-2023 | Relistor |
| Bioventus LLC | $36.24 | 2022 | |
| Forte Bio-Pharma LLC | $35.44 | 2023 | Prolate, Nalocet |
| Biodelivery Sciences International, INC. | $29.24 | 2021 | |
| Grt US Holding, INC. | $21.16 | 2022 | |
| Abbott Laboratories | $18.00 | 2025 | Eterna |
| Horizon Therapeutics Plc | $15.47 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $15.13 | 2021 | |
| Idorsia Pharmaceuticals US INC | $14.20 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brenda Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.